Exact Sciences, a molecular diagnostics company, completed the acquisition of Genomic Health, a provider of genomic-based diagnostic tests, for $2.8bn. As a result of the transaction's close, Genomic Health's common stock will now cease to be traded on the NASDAQ. "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company. I welcome the talented Genomic Health employees to the Exact Sciences family and look forward to leading our combined team as we enter our Company's next chapter," Kevin Conroy, Exact Sciences Chairman, and CEO.